Urinary osteopontin as a marker for localized and metastatic prostate cancer.

Prager, Alisa J.; Peng, Chuan; Lita, Elena; McNally, Deborah; Kaushal, A.; Sproull, Mary; Compton, Kathryn; Dahut, William L.; Figg, William D.; Camphausen, Kevin

doi:10.1200/jco.2011.29.15_suppl.e15147

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OPN is shown to promote chemoresistance 11 , stem cell properties / phenotype 12 , autophagy 13 , angiogenesis 14 , cell migration 15 , cell invasion 16 , 17 , metastasis via epithelial-mesenchymal transition 18 , 19 and immunosuppression in metastatic niche 20 in different cancers. It is also a prognostic marker in human cancers 21 including breast cancer 22 , 23 , colorectal cancer 24 , lung cancer 25 , 26 , head and neck squamous cell carcinoma 27 , gastric cancer 28 , 29 and prostate cancer 30 . We have also previously shown that OPN promotes breast cancer progression 23 , and have identified its upstream 31 , 32 and downstream targets 33 .…”

Section: Introductionmentioning

confidence: 99%

Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer

Wong¹,

Wei²,

Lyu³

et al. 2017

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Osteopontin (OPN) plays an important role in cancer progression, however its prognostic significance and its downstream factors are largely elusive. In this study, we have shown that expression of OPN was significantly higher in bladder cancer specimens with higher T-stage or tumor grades. In addition, a high level of OPN was significantly associated with poorer survival in two independent bladder cancer patient cohorts totaling 389 bladder cancer patients with available survival data. We further identified Matrix metallopeptidase 9 (MMP9) and S100 calcium-binding protein A8 (S100A8) were both downstream factors for OPN in bladder cancer specimens and bladder cancer cell lines. Expression of OPN was significantly positively associated with that of MMP9 and S100A8, while overexpression of OPN resulted in upregulation of MMP9 and S100A8, and knockdown of OPN showed consistent downregulation of MMP9 and S100A8 expression levels. Importantly, expression levels of both MMP9 and S100A8 were significantly associated with higher T-stage, higher tumor grade and a shorter survival time in the bladder cancer patients. Interestingly, OPN expression only predicted survival in MMP9-high, but not MMP9-low subgroups, and in S100A8-low but not S100A8-high subgroups. Our results suggest that OPN, MMP9 and S100A8 all play a significant role in bladder cancer progression and are potential prognostic markers and therapeutic targets in bladder cancer. The mechanistic link between these three genes and bladder cancer progression warrants further investigation.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer

Wong¹,

Wei²,

Lyu³

et al. 2017

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…With the exception of PSA, some available biomarkers such as urinary telopeptide X (uNTx), a marker of bone resorption, and osteopontin, a marker to distinguish localized and metastatic disease, are generally not widely endorsed for routine use in clinical practice. 40-42 Other analyses, such as circulating tumor analysis, which can identify disease features at the DNA or protein level will be useful biomarkers in the hospital setting. 43 The treatment of choice should also be based on patients’ characteristics and comorbidities, such as PSA doubling time, type of metastasis, and Gleason scores.…”

Section: Therapeutic and Economic Controversiesmentioning

confidence: 99%

Enzalutamide (Xtandi) for Patients With Metastatic, Resistant Prostate Cancer

Bennett

Ingason

2014

Ann Pharmacother

View full text Add to dashboard Cite

Enzalutamide is effective to slow progression of metastatic CRPC, to reduce prostate-specific antigen (PSA) levels, to decrease time to progression of PSA, to increase time to first skeletal-related events, and to increase quality of response rate. Enzalutamide was given at 160 mg/d for a median of 8 cycles of administration. Clinical trials are currently being conducted to observe if enzalutamide will be useful for treatment of other cancers and for early administration in prostate cancer.

show abstract